Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, open-label, multicenter, phase 2 trial assessing the efficacy and safety of apatinib combined with docetaxel and platinum as neoadjuvant treatment for triple-negative/HER2-positive breast cancer

Next Previous
Search
Trial Profile

A randomized, open-label, multicenter, phase 2 trial assessing the efficacy and safety of apatinib combined with docetaxel and platinum as neoadjuvant treatment for triple-negative/HER2-positive breast cancer

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 25 Jan 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rivoceranib (Primary) ; Carboplatin; Cisplatin; Docetaxel; Lobaplatin; Paclitaxel; Trastuzumab
  • Indications Advanced breast cancer; Early breast cancer; HER2 positive breast cancer
  • Focus Therapeutic Use

    • Most Recent Events

    • 11 Dec 2020 Primary endpoint has been met. (pathological complete response (pCR))
    • 11 Dec 2020 Results presented at the 43rd Annual San Antonio Breast Cancer Symposium
    • 20 Jan 2020 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top